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A B S T R A C T
Purpose
We assessed the safety and antitumor activity of avelumab, a fully human anti–programmed death-
ligand 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic urothelial carcinoma.
Methods
In this phase Ib, multicenter, expansion cohort, patients with urothelial carcinoma progressing after
platinum-based chemotherapy and unselected for PD-L1 expression received avelumab 10 mg/kg
intravenously every 2weeks. The primary objectiveswere safety and tolerability. Secondary objectives
included confirmed objective response rate (Response Evaluation Criteria in Solid Tumors [RECIST]
version 1.1), progression-free survival, overall survival (OS), and PD-L1–associated clinical activity.
PD-L1 positivity was defined as expression by immunohistochemistry on $ 5% of tumor cells.
Results
Forty-four patients were treated with avelumab and followed for a median of 16.5 months
(interquartile range, 15.8 to 16.7 months). The data cutoff was March 19, 2016. The most frequent
treatment-related adverse events of any grade were fatigue/asthenia (31.8%), infusion-related
reaction (20.5%), and nausea (11.4%). Grades 3 to 4 treatment-related adverse events occurred
in three patients (6.8%) and included asthenia, AST elevation, creatine phosphokinase elevation, and
decreased appetite. The confirmed objective response rate by independent central review was
18.2% (95% CI, 8.2% to 32.7%; five complete responses and three partial responses). The median
duration of response was not reached (95% CI, 12.1 weeks to not estimable), and responses were
ongoing in six patients (75.0%), including four of five complete responses. Seven of eight
responding patients had PD-L1–positive tumors. The median progression-free survival was
11.6 weeks (95% CI, 6.1 to 17.4 weeks); the median OS was 13.7 months (95% CI, 8.5 months to
not estimable), with a 12-month OS rate of 54.3% (95% CI, 37.9% to 68.1%).
Conclusion
Avelumab was well tolerated and associated with durable responses and prolonged survival in
patients with refractory metastatic UC.
J Clin Oncol 35:2117-2124. © 2017 by American Society of Clinical Oncology. Creative Commons At-
tribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
INTRODUCTION
Urothelial carcinoma of the bladder is a leading
cause of cancer deaths worldwide, with an esti-
mated 429,800 new cases reported in 2012.1 Pa-
tients with metastatic urothelial carcinoma are
typically treated with cisplatin-based combina-
tion chemotherapy in the first-line setting, with a
median overall survival (OS) of 14 to 15months.2,3
Prognostic factors associated with shorter OS
include poor performance status, visceral metas-
tasis, and low albumin or hemoglobin level.4
Second-line chemotherapies, such as paclitaxel,
pemetrexed, docetaxel, and vinflunine, have lim-
ited efficacy, with median survival of approxi-
mately 7 months.5-8
Immunotherapy with immune checkpoint
inhibitors, particularly agents targeting the pro-
grammed death-ligand 1/programmed death-1
(PD-L1/PD-1) axis, has improved treatment out-
comes in several tumor types.9 Immunotherapy
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for urothelial carcinoma began in 1990 with approval of the
intravesical bacillus Calmette-Gue´rin vaccine for non–muscle-
invasive disease.10,11 The rationale for assessing immune checkpoint
inhibitors in advanced urothelial cancer is supported by a high
prevalence of tumor somatic mutations,12 which may generate
neoantigens that are recognized by activated antitumor T cells.13,14
Such mutational signatures have been shown to correlate with re-
sponse to PD-L1/PD-1 antibodies in a range of advanced solid
tumors, including metastatic urothelial carcinoma.13,15 Atezolizu-
mab, an anti–PD-L1 agent, showed clinical activity in patients with
locally advanced or metastatic urothelial carcinoma after platinum-
based chemotherapy in a single-arm, phase II trial,16 which led to its
approval in the United States.17 Although levels of PD-L1 expression
on tumors and infiltrating lymphocytes in the tumor microenvi-
ronment have been associated with response to atezolizumab in
urothelial carcinoma in the second-line setting, the role of PD-L1 as
a predictive biomarker remains unclear.18,19
Avelumab (MSB0010718C) is an investigational fully human
anti–PD-L1 IgG1 antibody that inhibits PD-1/PD-L1 interactions
while leaving the PD-1/PD-L2 pathway intact20 and enhances
immune activation against tumor cells, as shown in preclinical
studies.21,22 Unlike other anti–PD-L1/PD-1 antibodies that are
approved or in advanced clinical development, avelumab induces
lysis of tumor cells via antibody-dependent cell-mediated cyto-
toxicity in vitro, suggesting an additional mechanism of action.23
Importantly, avelumab has not shown antibody-dependent cell-
mediated cytotoxicity against immune cell subsets in humans.21,24
A large, international, multicohort, phase I study was conducted to
assess the safety and clinical activity of avelumab in patients with
refractory advanced solid tumors. In the dose-escalation part of the
study, intravenous infusion of avelumab every 2 weeks was safe and
had a predictable pharmacokinetic profile at doses # 20 mg/kg.20
The 10 mg/kg dose was selected for study in phase Ib expansion
cohorts in a range of tumor types. Herein, we describe results in
a dose-expansion cohort of patients with metastatic urothelial
carcinoma.
METHODS
Study Design and Participants
JAVELIN Solid Tumor is an ongoing, phase I, open-label, multiple
ascending–dose trial designed to investigate the safety, tolerability, phar-
macokinetics, and biologic and clinical activity of avelumab in patients
with metastatic or locally advanced solid tumors, with expansion in se-
lected tumor types. In this phase Ib dose-expansion cohort, eligible pa-
tients had metastatic urothelial carcinoma of the renal pelvis, ureter,
urinary bladder, or urethra, as confirmed by histology or cytology. Eligible
patients were required to have relapsed, refractory, or progressive disease,
measurable by Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.1,25 following at least one previous line of treatment. The en-
rollment of cisplatin-ineligible patients (as a result of impaired renal
function, hearing loss of 25 dB over two contiguous frequencies, or
grade $ 2 peripheral neuropathy) was permitted after protocol amend-
ment on November 19, 2014.
Other eligibility criteria included age $ 18 years; life expectancy
$ 3 months; Eastern Cooperative Oncology Group performance status of
0-1; and adequate hepatic, renal (creatinine clearance. 30mL/min per the
Cockcroft-Gault formula or measured 24-hour creatinine clearance), and
hematologic functions. Patients were not preselected on the basis of
biomarkers, including PD-L1 expression on tumor cells or tumor-
associated immune cells. Concurrent anticancer treatment, immuno-
suppressive or hormonal agents, or prior therapy with any antibody/drug
Table 1. Select Baseline Characteristics
Characteristic N = 44
Median age, years (IQR) 68.0 (63.0-73.0)
Age category, no. (%)
, 65 years 11 (25.0)
$ 65 years 33 (75.0)
Sex, no. (%)
Male 30 (68.2)
Female 14 (31.8)
Race or ethnic group, no. (%)
White 39 (88.6)
Black or African American 2 (4.5)
Asian 2 (4.5)
Native Hawaiian or other
Pacific Islander
1 (2.3)
Geographic region, no. (%)
United States 38 (86.4)
Europe 6 (13.6)
ECOG PS, no. (%)
0 19 (43.2)
1 25 (56.8)
Subsite of tumor, no. (%)
Upper tract (renal pelvis or ureter) 7 (15.9)
Lower tract (bladder or urethra) 37 (84.1)
Visceral (nonlymph node) metastasis,
no. (%)*
Present 33 (75.0)
Absent 11 (25.0)
Smoking history, no. (%)
Never smoked 22 (50.0)
Ever smoked 22 (50.0)
Median time since first diagnosis,
months (IQR)
20.4 (11.6-46.6)
Median time since diagnosis of metastatic
disease, months (IQR)
14.2 (7.8-22.2)†
Eligibility status for prior platinum-based
therapy, no. (%)
Yes 44 (100.0)
No 0
No. of prior anticancer lines for advanced
disease, no. (%)
# 1 20 (45.5)
2 14 (31.8)
$ 3 10 (22.7)
Median, IQR 2, 1-2
PD-L1–positive expression status,
no. (%)‡
$ 1% tumor cells 14 (31.8)
$ 5% tumor cells 13 (29.5)
$ 25% tumor cells 5 (11.4)
$ 10% tumor-associated immune
cells
2 (4.5)
PD-L1–negative expression status,
no. (%)‡
$ 1% tumor cells 23 (52.3)
$ 5% tumor cells 24 (54.5)
$ 25% tumor cells 32 (72.7)
$ 10% tumor-associated immune cells 35 (79.5)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance
status; IQR, interquartile range; PD-L1, programmed death-ligand 1.
*Lung, liver, bone, or other nonlymph node metastasis.
†Forty-three patients had data for median time since diagnosis of metastatic
disease.
‡Thirty-seven patients were evaluable for PD-L1 expression. Nonevaluable
specimens (n = 7) included those that weremissing, of poor quality, or otherwise
not available to provide results.
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targeting T-cell coregulatory proteins were not permitted. Patients with
adrenal insufficiency could continue corticosteroids or topical steroids;
patients were tapered off all other steroids and immunosuppressive agents
before receiving study treatment (Data Supplement provides full inclusion
and exclusion criteria).
The study protocol (Clinical Trials.gov identifier: NCT01772004) was
approved by the institutional review board or independent ethics com-
mittee at each center, and patients were enrolled per international stan-
dards of good clinical practice and institutional safety monitoring. Patients
or their representatives provided written informed consent before study
entry, and all investigators signed Good Clinical Practice compliance
forms.
Procedures
Patients received avelumab (EMD Serono, Rockland, MA) 10 mg/kg
by 1-hour intravenous infusion once every 2 weeks until the criterion for
withdrawal occurred. Adverse events (AEs) were coded per Medical
Dictionary for Regulatory Activities terminology. The severity of an AEwas
classified according to the National Cancer Institute Common Termi-
nology Criteria for Adverse Events version 4.0.
Immune-related AEs and infusion-related reactions were of special
interest. Potential immune-related AEs were identified using a prespecified
list of Medical Dictionary for Regulatory Activities search terms followed
by medical review. An infusion-related reaction was classified by in-
vestigators as an AE in patients who had signs and symptoms of a potential
infusion-related reaction (eg, fever, chills, or rigors) on the day of treat-
ment or the next day. All patients were premedicated with an antihistamine
and acetaminophen (Data Supplement). Dose reductions were not per-
mitted; however, interruptions that resulted in, 90% of the planned dose
were considered dose reductions. Dose delays were specified following the
first occurrence of a grade 2 treatment-related adverse event (TRAE) that
did not resolve to grade # 1 by the last day in a treatment cycle.
Avelumab treatment was permanently discontinued following any
grade 3 or 4 TRAE except for single laboratory values out of normal range
that were considered unlikely to be as a result of trial treatment, did not
have any clinical correlate, and resolved to grade # 1 within 7 days with
medical management. Other exceptions were transient (# 6 hours) grade 3
flu-like symptoms or fever controlled with medical management; grade 3
fatigue, local reactions, headache, nausea, or emesis lasting # 24 hours;
grade$ 3 amylase or lipase abnormality not associated with symptoms or
clinical manifestations of pancreatitis; tumor flare phenomena (local pain,
irritation, or rash at site of tumor); and increase in Eastern Cooperative
Oncology Group performance status to $ 3.
Clinical activity was assessed by cross-sectional imaging (computed
tomography or magnetic resonance imaging) performed at baseline and
every 6 weeks and evaluated using RECIST version 1.1 to determine best
overall response and duration of response from the start of treatment until
documented disease progression. Images were reviewed locally by the
investigator and centrally by a blinded independent review committee.
Stable disease at the first postbaseline tumor assessment after 6 weeks was
required to qualify for a best response of stable disease.
PD-L1 expression in archived or fresh tumor biopsies was assessed
independently and blinded to any clinical data by immunohistochemistry
using a proprietary assay (Dako, Carpinteria, CA) on the basis of an
anti–PD-L1 rabbit monoclonal antibody clone (73-10), under license to
Merck KGaA. Tumors were categorized on the basis of quantity and in-
tensity of PD-L1 staining using percentage thresholds of $ 1% (any
intensity), $ 5% (any intensity), or $ 25% ($ 2+ staining intensity) in
tumor cell membranes, and $ 10% in hotspots of tumor-associated
immune cells (any intensity). Tumor-associated immune cells were
identified as nonmalignant cells on the basis of conventional morphologic
features detected in the PD-L1–stained section.
Outcomes
The primary objective was to assess the safety and tolerability of
avelumab, and the primary end point was occurrence of dose-limiting
toxicities during the first 3 weeks of treatment in the initial dose-escalation
part of the trial; these data are reported elsewhere.20 Key secondary end
points included best overall response according to RECIST by investigator
assessment and independent review committee, duration of response,
progression-free survival (PFS), OS, and evaluation of PD-L1 expression.
Other secondary end points (pharmacokinetic and pharmacodynamic
profile and immunogenicity of avelumab) will be analyzed across multiple
cohorts of this phase Ib study and reported elsewhere. Subgroup analyses
on the basis of patient and disease characteristics at baseline were con-
ducted post hoc.
Table 2. Treatment-Related Adverse Events Occurring At Any Grade in. 5% of Patients, or Grade$ 3 in Any Patient, or Classified As Immune Related in Any Patient
Adverse Events Among
Patients, N = 44 Any Grade, No. (%) Grades 1 to 2, No. (%) Grade 3, No. (%) Grade 4, No. (%)
Any event 29 (65.9) 26 (59.1) 2 (4.5) 1 (2.3)
Fatigue 9 (20.5) 9 (20.5) 0 0
Infusion-related reaction* 9 (20.5) 9 (20.5) 0 0
Asthenia 5 (11.4) 4 (9.1) 1 (2.3) 0
Nausea 5 (11.4) 5 (11.4) 0 0
Diarrhea 4 (9.1) 4 (9.1) 0 0
Rash† 4 (9.1) 4 (9.1) 0 0
Hypothyroidism† 3 (6.8) 3 (6.8) 0 0
Pruritus† 3 (6.8) 3 (6.$8) 0 0
Decreased appetite 2 (4.5) 1 (2.3) 1 (2.3) 0
Elevated AST† 2 (4.5) 1 (2.3) 1 (2.3) 0
Elevated CPK 1 (2.3) 0 0 1 (2.3)
Elevated ALT† 1 (2.3) 1 (2.3) 0 0
Pneumonitis† 1 (2.3) 1 (2.3) 0 0
Rheumatoid arthritis† 1 (2.3) 1 (2.3) 0 0
Uveitis† 1 (2.3) 1 (2.3) 0 0
Abbreviation: CPK, creatine phosphokinase.
*Signs and symptoms of a potential infusion-related reaction (eg, fever, chills, or rigors) reported on the day of infusion were queried with investigators to ascertain
whether an adverse event of “infusion-related reaction” should be recorded.
†Adverse event types that were considered to be potentially immune related. Rash was classified as immune related by medical review in three patients, and elevated
AST (grade 3) and pruritus were classified as immune related in one patient each. All other adverse events marked with the dagger symbol (†) were classified as immune
related for all cases shown in the table. Rash includes preferred terms rash, rash maculopapular, rash pruritic, and rash erythematous.
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Statistical Analyses
The enrollment of approximately 50 patients was planned in this
cohort. Safety and clinical activity were analyzed in all patients who re-
ceived at least one dose of avelumab. The study was designed to estimate
the objective response rate (ORR; proportion of patients with a confirmed
best response of complete or partial response) using 95% Clopper-Pearson
CIs. Time-to-event outcomes, such as duration of response, PFS, and OS,
were estimated using Kaplan-Meier methodology, and corresponding CIs
were calculated using Brookmeyer-Crowley methodology. Because of fa-
vorable preliminary clinical activity, enrollment was stopped after 44
patients to open a larger urothelial cohort with an additional primary end
point of best overall response according to independent central review per
RECIST within the same multicohort study.
Role of the Funding Source
The sponsor, Merck KGaA (Darmstadt, Germany), provided the
study drug and helped investigators design the trial, collect and analyze
data, and interpret results. All authors participated fully in the develop-
ment of the manuscript for publication. Funding for a professional medical
writer with access to the data was provided by the sponsor and Pfizer (New
York, NY), for initial drafts of the manuscript.
RESULTS
Between September 3, 2014, and December 9, 2014, 66 patients
were screened. Of these, 44 patients with metastatic urothelial
carcinoma that had progressed following platinum-based che-
motherapy were enrolled and treated at 24 sites in the United States
and Europe (Data Supplement). No cisplatin-ineligible patients
were enrolled. At the time of data cutoff on March 19, 2016,
patients had been followed for a median of 16.5 months
(interquartile range [IQR], 15.8-16.7 months) and a minimum of
15.0 months; six of 44 patients (13.6%) remained on treatment.
Disease progression was the most common reason for discon-
tinuation (31 patients [70.5%]; Data Supplement).
The median age of patients was 68.0 years (IQR, 63.0-73.0
years); 30 of 44 patients (68.2%) were male (Table 1). The subsite
of the primary tumor was in the lower tract (bladder or urethra) in
37 patients (84.1%) and the upper urinary tract (renal pelvis or
ureter) in seven patients (15.9%). Thirty-three patients (75.0%)
had visceral metastases (defined as lung, liver, bone, or other
nonlymph node sites).
All patients were eligible for platinum-based chemotherapy
and had been treated with at least one prior line of systemic therapy
(Data Supplement). Twenty-four patients (54.5%) had received at
least two prior anticancer regimens for advanced disease (Table 1).
Specimens from 37 patients (84.1%) were evaluable for PD-L1
expression (Table 1 and Data Supplement). Across all expression
thresholds, most tumors were PD-L1– on the basis of assessment of
tumor cells or tumor-associated immune cells. Using a $ 5%
staining threshold in tumor cells, 13 patients (29.5%) had PD-
L1–positive tumors.
Patients received a median of seven doses of avelumab
(IQR, 3-17 doses) for a median duration of 14.1 weeks (IQR,
6.0-35.1 weeks). Dosing was delayed in 17 of 44 patients (38.6%),
for 3-6 days in four patients (9.1%), and for$ 7 days in 13 patients
(29.5%). The planned dose was reduced once in one patient
(2.3%).
All patients had an AE (Data Supplement); 29 of 44 (65.9%)
had a TRAE (Table 2 and Data Supplement). The most common
TRAEs of any grade were fatigue (n = 9 [20.5%]), infusion-related
reaction (n = 9 [20.5%]), asthenia (n = 5 [11.4%]), and nausea
(n = 5 [11.4%]). Symptoms of infusion-related reactions included
chills/rigors, fever, hypertension, headache, flushing, dizziness,
sweating, and leg cramps within 24 hours of infusion. Treatment
modifications following infusion-related reactions were as follows:
grade 1, infusion rate decreased by 50% with close monitoring for
worsening; and grade 2, infusion stopped and resumed at 50% of
the previous rate after resolution or decrease to grade 1, with close
monitoring for worsening.
Four grade 3 to 4 TRAEs occurred in three patients (6.8%):
grade 4 elevated blood creatine phosphokinase and grade 3 AST
elevation (both events occurred in the same patient, who also
experienced grade 2 hypothyroidism), grade 3 asthenia, and grade
3 decreased appetite. Nineteen of 44 patients (43.2%) had a serious
AE (Data Supplement), considered a TRAE in two patients: ele-
vated creatine phosphokinase and AST (same patient) and as-
thenia. Avelumab was permanently discontinued in four patients
(9.1%) following a TRAE: grade 3 elevated AST, grade 2 infusion-
related reaction, grade 2 uveitis, and grade 2 arthralgia, respectively.
No treatment-related renal toxicities were reported. Nine patients
(20.5%) had a TRAE of any grade that was potentially immune
related, most commonly hypothyroidism (n = 3 [6.8%]; Table 2).
There were no treatment-related deaths. Seven deaths (15.9%)
occurred that were not treatment-related, with six (13.6%) as
a result of disease progression and one (2.3%) attributed to re-
spiratory failure as a result of disease progression.
On the basis of independent central review assessment,
treatment with avelumab resulted in a confirmed ORR of 18.2%
(95% CI, 8.2 to 32.7) and a disease control rate of 52.3%, including
five patients (11.4%) with a complete response, three patients
(6.8%) with a partial response, and 15 patients (34.1%) with stable
disease as best response (Table 3 and Fig 1A). Five of the eight
responding patients (62.5%) had visceral (nonlymph node) me-
tastases (Fig 1B). The unconfirmed ORR was 27.3% (95% CI, 15.0
Table 3. Clinical Activity of Avelumab
Clinical Activity End Point
Avelumab
(N = 44), No. (%)
Confirmed best response, no. (%)
Complete response 5 (11.4)
Partial response 3 (6.8)
Stable disease 15 (34.1)
Progressive disease 15 (34.1)
Nonevaluable* 6 (13.6)
Confirmed ORR, % (95% CI) 18.2 (8.2 to 32.7)
Disease control rate, % 52.3
Median PFS, weeks (95% CI) 11.6 (6.1 to 17.4)
PFS rate at 48 weeks, % (95% CI) 19.1 (8.5 to 32.8)
Median OS, months (95% CI) 13.7 (8.5 to ne)
OS rate at 12 months, % (95% CI) 54.3 (37.9 to 68.1)
Abbreviations: ne, not estimable; ORR, overall response rate; OS, overall
survival; PFS, progression-free survival.
*Missing and/or not assessable information: five patients had no postbaseline
tumor assessment (four patients diedwithin 6weeks and onewithdrew from the
study), and one patient who initiated a new anticancer therapy before the first
postbaseline assessment.
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Fig 1. Clinical activity of avelumab. (A)
Time to response, duration of treatment, and
duration of response to avelumab (eight
confirmed responses and four unconfirmed
responses as of data cutoff), with pro-
grammed death-ligand 1 (PD-L1) expression
status indicated (on the basis of a $ 5%
staining threshold on tumor cells; non-
evaluable specimens [n = 7] included those
that were missing, of poor quality, or oth-
erwise not available to provide results). The
vertical dotted line represents 1 year from
the initiation of treatment. (B) Plot of tumor
regression from baseline as measured by
Response Evaluation Criteria in Solid Tumors
(RECIST) in all assessable patients (n = 38),
with PD-L1 expression status indicated (on
the basis of a $ 5% staining threshold on
tumor cells). Eastern Cooperative Oncology
Group (ECOG) performance status, pres-
ence of nonlymph node metastasis, and al-
bumin and hemoglobin levels at baseline are
shown for each patient. The upper dotted
line represents progression at 20% and the
lower dotted line represents the RECIST
boundary for complete response or partial
response at 30%. (C) Percentage change in
sum of target lesion diameters from baseline
over time for all assessable patients (n = 38),
defined as those patients with baseline tu-
mor assessments and at least one post-
baseline assessment. The upper dotted line
represents progression at 20% and the
lower dotted line represents the RECIST
boundary for complete response or partial
response at 30%.
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to 42.8), including five complete responses and seven partial re-
sponses. Reasons for lack of response confirmation were devel-
opment of new lesion (n = 3) and no subsequent on-study tumor
assessment (n = 1).
In patients with a confirmed response, the median time to
response on the basis of independent review was 13.0 weeks
(IQR, 8.8-38.6 weeks), and the median duration of response
was not reached (95% CI, 12.1 weeks to not estimable). Re-
sponses were ongoing at the time of analysis in six of eight
patients (75.0%; durations of $ 17.7 to $ 65.7 weeks), in-
cluding four of five patients with a complete response, and
were maintained for $ 48 weeks in 70.0% of patients (95%
CI, 22.5% to 91.8%) by Kaplan-Meier estimates. Thirteen of
44 patients (29.5%) had a reduction in target lesions by
$ 30% from baseline; six patients were nonevaluable (Figs 1B
and 1C).
The median PFS was 11.6 weeks (95% CI, 6.1 to 17.4 weeks);
the proportion of patients who were free of disease progression at
48 weeks was 19.1% (95% CI, 8.5% to 32.8%; Table 3 and Fig 2A).
The median OS was 13.7 months (95% CI, 8.5 months to not
estimable), and the 12-month OS rate was 54.3% (95% CI, 37.9%
to 68.1%; Table 3 and Fig 2B). Sixteen patients (36.4%) received
anticancer therapy after discontinuing avelumab; of these,
13 (29.5%) had drug therapy, including cytotoxic chemotherapy
(n = 9; 20.5%), kinase inhibitor (n = 5; 11.4%), and investigational
antibody (n = 2; 4.5%).
Among 37 patients evaluable for PD-L1 expression, responses
occurred in patients with PD-L1–positive and PD-L1–negative
tumors at all prespecified PD-L1 expression–level thresholds, al-
though trends toward higher response rates and longer PFS and OS
were seen in patients with PD-L1–positive tumors (Figs 1A, 2C and
2D, and Data Supplement). On the basis of a $ 5% threshold for
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Fig 2. Progression-free survival (PFS) and overall survival (OS). Kaplan-Meier estimate of PFS (A) and OS (B) for the overall study population (N = 44). Kaplan-Meier
estimate of PFS (C) and OS (D) on the basis of programmed death-ligand 1 (PD-L1) expression on tumor cells (n = 37). Vertical lines show censored events. Positive PD-L1
expression was defined as $ 5% of tumor cells expressing PD-L1 at any intensity. ne, not estimable.
2122 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Apolo et al
Downloaded from ascopubs.org by Henry Ford Hospital on December 18, 2019 from 150.198.017.009
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
staining on tumor cells, seven of eight responding patients (87.5%)
had PD-L1–positive tumors. The confirmed ORR by independent
review was 53.8% in PD-L1–positive tumors (seven of 13) and
4.2% in PD-L1–negative tumors (one of 24).
Responses occurred in patients who had factors associated
with poor prognosis. Confirmed ORRs by independent central
review were 15.2% (five of 33) and 27.3% (three of 11) in patients
with or without visceral (nonlymph node) metastases at baseline,
respectively, and 30.0% (three of 10) and 10.0% (two of 20) in
patients with $ 3 or # 1 prior anticancer lines for advanced
disease, respectively. There were no confirmed responses in pa-
tients with low albumin or hemoglobin levels (0.0% [zero of eight]
and 22.2% [eight of 36] in patients with baseline albumin levels
, 35 g/L or $ 35 g/L, respectively, and 0.0% [zero of seven] and
21.6% [eight of 37] in patients with baseline hemoglobin levels
, 100 g/L or$ 100 g/L, respectively). The median PFS in patients
with or without visceral (nonlymph node) metastases (11.4 v
11.6 months) was similar to that in the overall cohort.
DISCUSSION
In this study of 44 patients with refractory metastatic urothelial
carcinoma who were followed for a median of 16.5 months,
avelumab was well tolerated and showed promising clinical ac-
tivity, which was characterized by durable responses, disease sta-
bilization, and prolonged OS. The confirmed ORR of 18.2% is
notably higher than a historical control rate of 10% for chemo-
therapy8 and included a complete response in 11.4% of patients.
Importantly, responses were ongoing at the time of analysis
(minimum 15 months of follow-up) in 75.0% of responding
patients, including four of the five patients with a complete re-
sponse. Responses were also notable in patients with visceral
(nonlymph node) metastases (15.2%) and heavily pretreated pa-
tients (30.0% in those patients who had received at least three prior
anticancer lines in the advanced setting), indicating that avelumab
may have clinical benefit in subpopulations with a poor prognosis.
However, no confirmed response to avelumab occurred in patients
with low albumin or hemoglobin levels, each of which is a known
poor prognostic feature in metastatic urothelial carcinoma. The
median OS was 13.7 months. The 12-month OS rate was 54.3%,
which is highly encouraging compared with vinflunine8 and other
chemotherapy regimens26 in the second-line setting, and is con-
sistent with other anti–PD-L1/PD-1 antibodies.16,27-29 A potential
trend toward greater clinical activity of avelumab was seen in
patients with PD-L1–positive tumors, although patients with PD-
L1–negative tumors also had responses. These analyses are ex-
ploratory, and the potential use of PD-L1 as a predictive biomarker
for avelumab is being further analyzed.
Key safety findings included a low rate of grade $ 3 TRAEs
(6.8%), a low incidence of immune-related AEs (20.5%, most of
which were grade 1 or 2), and no treatment-related renal toxicities
or treatment-related deaths. In studies of other anti–PD-L1/PD-1
antibodies in advanced urothelial carcinoma, rates of grade 3 to 4
TRAEs ranged from 4.9% to 21.8%.16,27-29 The most common
TRAEs with avelumab were fatigue, infusion-related reaction,
asthenia, and nausea, which were mostly grades 1 or 2. One patient
discontinued treatment as the result of a grade 2 infusion-related
reaction. The mechanism leading to infusion-related reaction
during avelumab treatment is currently unknown; detailed analysis
across various tumor types is ongoing.
In conclusion, findings from this study suggest that avelumab
could become a potential treatment option for patients with ad-
vanced urothelial carcinoma. On the basis of the promising clinical
activity seen in this cohort of the JAVELIN Solid Tumor trial, an
additional expansion cohort of approximately 200 patients with
urothelial carcinoma has been enrolled to further characterize the
efficacy and safety of avelumab in this patient population. In
addition, a randomized phase III trial of avelumab plus best
supportive care versus best supportive care alone as maintenance
therapy in patients with metastatic urothelial carcinoma not
progressing after first-line platinum-based therapy is underway
(NCT02603432).
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